<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125380</url>
  </required_header>
  <id_info>
    <org_study_id>FBKS 2019-6</org_study_id>
    <nct_id>NCT05125380</nct_id>
  </id_info>
  <brief_title>Cervical Cancer Screening by Self-sampling in a Cohort of Younger Women in Ethiopia</brief_title>
  <official_title>Evaluation of an Human Papillomavirus (HPV) Based Screening Algorithm for Low and Middle Income Countries, by Self-sampling in Ethiopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Adama Hospital Medical College, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of the project is to evaluate an algorithm for an HPV self-sampling based&#xD;
      cervical cancer screening algorithm in a mid-size town in Ethiopia that could be applicable&#xD;
      for nationwide implementation in low and middle-income countries (LMIC).&#xD;
&#xD;
      Specific aims are the following:&#xD;
&#xD;
        -  To evaluate the algorithm using Visual Inspection with Acetic acid (VIA) and VIA&#xD;
           together with Lugol's Iodine (VILI) as triage and to use HPV self-sample to follow up&#xD;
           those treated and those with persisting HPV.&#xD;
&#xD;
        -  To evaluate the prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae and their&#xD;
           effect on the quality of VIA.&#xD;
&#xD;
        -  To determine immune response profiles in high-risk HPV-positive women who cleared,&#xD;
           persisted, or developed Cervical Intraepithelial Neoplasia 2/3 (CIN).&#xD;
&#xD;
        -  To assess how specific cervicovaginal microbiota compositions are associated with HPV&#xD;
           infection, cervical dysplasia, and cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The whole cohort is offered an HPV self-sample. The HPV high risk positive women gets randomised into two arms VIA or VIA/VILI at the triage step.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of VIA and VIA/VILI as triage test</measure>
    <time_frame>12 weeks</time_frame>
    <description>All HPV pos women will have a cervical biopsy taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of STI other than HPV</measure>
    <time_frame>8 weeks</time_frame>
    <description>Chlamydia Trachomatis, Neisseria Gonnorhea, Ureaplasma Urelytikum/Parvum, Trichomonas Vaginalis, Mycoplasma Genitalium/Hominis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Microbiota composition</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed in HPV high risk pos women at initiation, who persist and who clear their infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>STI</condition>
  <condition>Human Papilloma Virus</condition>
  <condition>Microbiota</condition>
  <arm_group>
    <arm_group_label>1- Triage arm for HPV pos women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HPV positive women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- Triage arm for HPV pos women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV positive women</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)</intervention_name>
    <description>A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.</description>
    <arm_group_label>2- Triage arm for HPV pos women</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VIA (Visual Inspection with Acetic acid)</intervention_name>
    <description>A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.</description>
    <arm_group_label>1- Triage arm for HPV pos women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Can give consent, Age above 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who have undergone hysterectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adane Mihret, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armauer Hansen Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selamawit Mekuria, MD</last_name>
    <phone>+46720123974</phone>
    <email>selamawit.mekuria@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mats Jerkeman, MD, PhD</last_name>
    <phone>+46704973507</phone>
    <email>mats.jerkeman@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adama and Geda Health Center</name>
      <address>
        <city>Ä€dama</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adamu Meghersa</last_name>
      <email>adamumeghersa@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LMIC Lowe Middle income country</keyword>
  <keyword>Screening</keyword>
  <keyword>Vaginal microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetic Acid</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
    <mesh_term>Lugol's solution</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

